Literature DB >> 11254869

The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer.

M Los1, E E Voest.   

Abstract

Antivascular therapy may be considered as one of the most promising approaches in the treatment of cancer. Antivascular treatment may be divided in antiangiogenesis and vascular targeting. Antiangiogenic therapy prevents neovascularization by inhibiting proliferation, migration, and/or differentiation of endothelial cells. Vascular targeting is directed at the existing tumor vasculature. Several inhibitors of angiogenesis are currently being tested in clinical cancer trials. The challenge for the next decade is to incorporate antivascular approaches into conventional treatment strategies. This review will summarize the conceptual basis of antivascular therapy and discuss the potential role of these agents in the adjuvant, neoadjuvant, and perioperative treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254869     DOI: 10.1016/s0093-7754(01)90047-8

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

1.  Targeted therapies for killing tumor cells.

Authors:  A F Gazdar; J D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies.

Authors:  Daniel Q McNerny; Jolanta F Kukowska-Latallo; Douglas G Mullen; Joseph M Wallace; Ankur M Desai; Rameshwer Shukla; Baohua Huang; Mark M Banaszak Holl; James R Baker
Journal:  Bioconjug Chem       Date:  2009-10-21       Impact factor: 4.774

Review 3.  The biology of the combretastatins as tumour vascular targeting agents.

Authors:  Gillian M Tozer; Chryso Kanthou; Charles S Parkins; Sally A Hill
Journal:  Int J Exp Pathol       Date:  2002-02       Impact factor: 1.925

Review 4.  Antiangiogenic therapy in brain tumors.

Authors:  Sajani S Lakka; Jasti S Rao
Journal:  Expert Rev Neurother       Date:  2008-10       Impact factor: 4.618

5.  Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model.

Authors:  Hairong Xu; Xiaohui Niu; Qing Zhang; Lin Hao; Yi Ding; Weifeng Liu; Lu Yao
Journal:  Oncol Lett       Date:  2011-07-04       Impact factor: 2.967

6.  Radiotherapy in combination with vascular-targeted therapies.

Authors:  Eva Ciric; Gregor Sersa
Journal:  Radiol Oncol       Date:  2010-05-24       Impact factor: 2.991

7.  Selectivity of the photosensitiser Tookad for photodynamic therapy evaluated in the Syrian golden hamster cheek pouch tumour model.

Authors:  F Borle; A Radu; C Fontolliet; H van den Bergh; P Monnier; G Wagnières
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.